UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway

Science (American Association for the Advancement of Science), 2018-08, Vol.361 (6405)

2018

Volltextzugriff (PDF)

Adaptive stress signaling in targeted cancer therapy resistance

Oncogene, 2015-11, Vol.34 (45), p.5599-5606

2015

Volltextzugriff (PDF)

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation

Oncogene, 2016-03, Vol.35 (9), p.1198-1205

2016

Volltextzugriff (PDF)

Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment

Molecular cell, 2004-02, Vol.13 (3), p.341-355

2004

Volltextzugriff (PDF)

Membranes as messengers in T cell adhesion signaling

Nature immunology, 2004-04, Vol.5 (4), p.363-372

2004

Volltextzugriff (PDF)

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation

Oncogene, 2016-03, Vol.35 (9), p.1198-1205

2016

Volltextzugriff (PDF)

Ras pathway signaling on endomembranes

Current opinion in cell biology, 2003-04, Vol.15 (2), p.136-142

2003

Volltextzugriff (PDF)

Ras Activation in Jurkat T cells following Low-Grade Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the Golgi Apparatus

Molecular and Cellular Biology, 2004-04, Vol.24 (8), p.3485-3496

2004

Volltextzugriff (PDF)

Intersectin Activates Ras but Stimulates Transcription through an Independent Pathway Involving JNK

The Journal of biological chemistry, 2003-11, Vol.278 (47), p.47038-47045

2003

Volltextzugriff (PDF)

Targeting AXL in NSCLC

Lung cancer (Auckland), 2021-01, Vol.12, p.67-79

2021

Volltextzugriff (PDF)

Oncogenic activation of the PI3-kinase p110[beta] isoform via the tumor-derived PIK3C[beta]D1067V kinase domain mutation

Oncogene, 2016-03, Vol.35 (9), p.1198

2016

Volltextzugriff (PDF)

Oncogenic activation of the PI3-kinase p110 beta isoform via the tumor-derived PIK3C beta super(D1067V) kinase domain mutation

Oncogene, 2016-03, Vol.35 (9), p.1198-1205

2016

Volltextzugriff (PDF)

PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis

Molecular cell, 2006-02, Vol.21 (4), p.481-493

2006

Volltextzugriff (PDF)

Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1

Nature (London), 2003-08, Vol.424 (6949), p.694-698

2003

Volltextzugriff (PDF)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC

Lung cancer (Auckland), 2015-01, Vol.6 (default), p.27-34

2015

Volltextzugriff (PDF)

Rap1 Up-Regulation and Activation on Plasma Membrane Regulates T Cell Adhesion

The Journal of cell biology, 2004-02, Vol.164 (3), p.461-470

2004

Volltextzugriff (PDF)

Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations

The EMBO journal, 2004-04, Vol.23 (8), p.1749-1760

2004

Volltextzugriff (PDF)

Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains

Methods (San Diego, Calif.), 2005-10, Vol.37 (2), p.138-145

2005

Volltextzugriff (PDF)

Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca super(2+) oscillations

The EMBO journal, 2004-04, Vol.23 (8), p.1749-1760

2004

Volltextzugriff (PDF)

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Chemotherapy Research and Practice, 2012-01, Vol.2012 (2012), p.186-194

2012

Volltextzugriff (PDF)

Understanding and targeting resistance mechanisms in NSCLC

Nature reviews. Cancer, 2017-11, Vol.17 (11), p.637-658

2017

Volltextzugriff (PDF)

Polytherapy and Targeted Cancer Drug Resistance

Trends in Cancer, 2019-03, Vol.5 (3), p.170-182

2019

Volltextzugriff (PDF)

Current Landscape of Targeted Therapy in Lung Cancer

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.757-764

2017

Volltextzugriff (PDF)

Targeting Oncogenic BRAF: Past, Present, and Future

Cancers, 2019-08, Vol.11 (8), p.1197

2019

Volltextzugriff (PDF)

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

Current opinion in chemical biology, 2021-06, Vol.62, p.1-12

2021

Volltextzugriff (PDF)

1 – 25 von 368

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(327)
Mit Volltextzugriff
(325)

Publikationsform

Sprache

Englisch
(366)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway

Adaptive stress signaling in targeted cancer therapy resistance

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation

Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment

Membranes as messengers in T cell adhesion signaling

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation

Ras pathway signaling on endomembranes

Ras Activation in Jurkat T cells following Low-Grade Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the Golgi Apparatus

Intersectin Activates Ras but Stimulates Transcription through an Independent Pathway Involving JNK

Targeting AXL in NSCLC

Oncogenic activation of the PI3-kinase p110[beta] isoform via the tumor-derived PIK3C[beta]D1067V kinase domain mutation

Oncogenic activation of the PI3-kinase p110 beta isoform via the tumor-derived PIK3C beta super(D1067V) kinase domain mutation

PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis

Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1

AXL receptor tyrosine kinase as a therapeutic target in NSCLC

Rap1 Up-Regulation and Activation on Plasma Membrane Regulates T Cell Adhesion

Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations

Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains

Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca super(2+) oscillations

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Understanding and targeting resistance mechanisms in NSCLC

Polytherapy and Targeted Cancer Drug Resistance

Current Landscape of Targeted Therapy in Lung Cancer

Targeting Oncogenic BRAF: Past, Present, and Future

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

Suchergebnisse filtern